Abstracts Archive - Page 1721 of 2425 - ACR Meeting Abstracts

Abstract Number: 472 • 2015 ACR/ARHP Annual Meeting
Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?
Jose Luis Andreu^1,2, Maria Auxiliadora Martin³, H Corominas⁴, Jose Javier Perez Venegas⁵, Jose Andres Roman Ivorra^6,7, Angel Gil⁸, Fernando Sánchez-Alonso⁹, Tamara Jiménez¹⁰ and Miguel Angel Sánchez-Ruiz¹⁰, ¹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ²Rheumatology, HU Puerta de Hierro Majadahonda, Madrid, Spain, ³Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ⁴CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁶Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁷Servicio de Reumatología, Servicio de Reumatología Hospital Universitario La Fe, Valencia, Spain, ⁸Cátedra de Resultados en Salud, Universidad Rey Juan Carlos, Madrid, Spain, ⁹Unidad de Investigación. Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Universidad Rey Juan Carlos, Madrid, Spain
Background/Purpose: The current paradigm of optimal clinical management of patients with rheumatoid arthritis (RA) recommends reaching a state of remission or low activity of the disease,…
Abstract Number: 473 • 2015 ACR/ARHP Annual Meeting
Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
Leena R Baghdadi^1,2,3, Richard J Woodman², E Michael Shanahan⁴ and Arduino A Mangoni³, ¹Department of Family and Community Medicine, King Saud University, Riyadh, Saudi Arabia, ²Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia, ³Department of Clinical Pharmacology, Flinders University, Adelaide, Australia, ⁴Department of Rheumatology, Flinders University, Adelaide, Australia
Background/Purpose: Methotrexate (MTX) use has been associated with reduced cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Although MTX has anti-inflammatory effects, there…
Abstract Number: 474 • 2015 ACR/ARHP Annual Meeting
Trends in the Use of Opiates in Rheumatoid Arthritis (RA) Compared to Non-RA: A Population Based Study in 2003-2012
J.A. Zamora-Legoff¹, Sara J. Achenbach², Cynthia S. Crowson³, John M. Davis III¹ and Eric L. Matteson⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Opiates are often used to treat difficult to manage pain, however, little is known about the trends of use for opiates in a modern…
Abstract Number: 475 • 2015 ACR/ARHP Annual Meeting
Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry
Arthur Kavanaugh¹, Carol J. Etzel^2,3, Wendi Malley³, Chitra Karki³, Jeffrey D. Greenberg^3,4, Yanjun Bao⁵, Naijun Chen⁵ and Vishvas Garg⁶, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴NYU School of Medicine, New York, NY, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie, North Chicago, IL
Background/Purpose: Based on international task force recommendations, the primary goal of rheumatoid arthritis (RA) treatment is to: achieve control of symptoms to greatest extent possible,…
Abstract Number: 476 • 2015 ACR/ARHP Annual Meeting
Clinical Disease Activity Measures Change Substantially and Irregularly over Time in Individual Rheumatoid Arthritis Patients Considered to be in Steady State
Ole Rintek Madsen^1,2 and Emilie Lund Egsmose³, ¹Department of Reumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²The DANBIO registry, Copenhagen University Hospital Glostrup Rigshospitalet, Glostrup, Denmark, ³Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Assessment of clinical markers of disease activity is routine in monitoring patients with rheumatoid arthritis (RA) in daily practice. Changes in clinical measures may…
Abstract Number: 477 • 2015 ACR/ARHP Annual Meeting
On-Demand Use of Etanercept Only for Disease Flares Reduced the Disease Activity Score and Structural Damage Equivalent to Fully-Use of Etanercept in RA Patients
Kentaro Inui¹, Tatsuya Koike², Masahiro Tada³, Yuko Sugioka², Kenji Mamoto⁴, Tadashi Okano⁴, Akira Sakawa⁵, Kenzo Fukushima⁶ and Hiroaki Nakamura⁴, ¹Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City General Hospital, OSAKA, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka City Juso Hospital, Osaka, Japan, ⁶Orthopaedic Surgery, Fujiidera Municipal Hospital, Fujiidera, Japan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) are essential in the treatment of rheumatoid arthritis (RA). Biological DMARDs are particularly recommended for patients with active RA…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 479 • 2015 ACR/ARHP Annual Meeting
How to Recruit Anti-CCP Positive Patients from Primary Care
Jackie L. Nam¹, Laura Hunt¹, Elizabeth M.A. Hensor¹ and Paul Emery^1,2, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Around 1% of the population test positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies. This biomarker predicts progression to rheumatoid arthritis (RA) but over a…
Abstract Number: 480 • 2015 ACR/ARHP Annual Meeting
Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown³, Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Angèle Turcotte³, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁴Rhumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: The recent publication of the concerto trial comparing the use of adalimumab in monotherapy versus in association with methotrexate (MTX) at dose varying from…
Abstract Number: 481 • 2015 ACR/ARHP Annual Meeting
Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis – Single Center Experience
Rok Ješe¹, Aleš Ambrožič¹, Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Martina Plešivčnik Novljan², Sonja Praprotnik¹, Ziga Rotar¹, Alenka Šipek Dolničar¹ and Matija Tomšič¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset is associated with a significant benefit in…
Abstract Number: 482 • 2015 ACR/ARHP Annual Meeting
Erosions in the Foot at Baseline Are Predictive of Orthopedic Shoe Use after 10 Years of Treat to Target Therapy
Sytske Anne Bergstra¹, Rosaline van den Berg², Naghmeh Riyazi³, Gerda M. Steup-Beekman⁴, Peter A.H.M. van der Lubbe⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, T. W. J. Huizinga⁸, Robert B.M. Landewé^9,10 and Cornelia F. Allaart¹, ¹Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Vlietland Hospital, Schiedam, Netherlands, ⁶Department of Rheumatology, Reade, Amsterdam, Netherlands, ⁷Department of Rheumatology, VU Universitary Medical Center, Amsterdam, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ¹⁰Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: Orthopaedic shoes (OS) may help to reduce pain and increase activity participation in rheumatoid arthritis (RA) patients, but should ideally not be needed. We…
Abstract Number: 483 • 2015 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Ted R. Mikuls¹, Brian Coburn¹, Harlan Sayles², Fang Yu³, Mary Brophy⁴, James R. O'Dell¹, Lynell W. Klassen⁵ and Geoffrey M. Thiele¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Heathcare System, Boston, MA, ⁵Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Previous reports have demonstrated that malondialdehyde-acetaldehyde (MAA) adducts are produced as a byproduct of oxidative stress and lipid peroxidation and are expressed in…
Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Myriam Guevara¹, Bernard NG¹ and Nancy Gove², ¹Rheumatology, University of Washington, Seattle, WA, ²Biostatistics, Seattle Children's, Seattle, WA
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
Abstract Number: 485 • 2015 ACR/ARHP Annual Meeting
Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
Xin Zhang, Laiyi Chua, C. Steven Ernest II, William Macias, Terence Rooney and Lai San Tham, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari) is an oral inhibitor of Janus kinases (JAK) selective for JAK 1 and 2. It has demonstrated dose-dependent efficacy in patients with…
Abstract Number: 486 • 2015 ACR/ARHP Annual Meeting
Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort
Dennis Parenti¹, Shelly Kafka¹, George W. Reed², Jeffrey D. Greenberg^2,3 and Raphael DeHoratius^1,4, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Corrona, LLC, Southborough, MA, ³NYU School of Medicine, New York, NY, ⁴Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The objective of this analysis was to examine persistence with intravenous (IV) and subcutaneous (SC) anti-TNF therapies among rheumatoid arthritis (RA) patients (pts) within…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].